| Literature DB >> 34104248 |
Iryna Ivanivna Kamyshna1, Larysa Borysivna Pavlovych2, Vitaliy Antonovych Maslyanko2, Aleksandr Mychailovich Kamyshnyi3.
Abstract
The thyroid hormone plays a vital role in the development and maturation of the nervous system not only during prenatal and perinatal age but also in adults. "Peripheral marker hypothesis" revealed that gene expression changes in some regions of the brain are reflected into the peripheral blood lymphocytes. The objective of the study was to investigate changes in the gene expression profile of neuropeptides and their receptors in patients with different forms of thyroid pathology. One hundred fifty-three patients with thyroid pathology were enrolled in the study. They were divided into three groups: group 1 included 16 patients with postoperative hypothyroidism, group 2 included 65 patients with hypothyroidism resulting from autoimmune thyroiditis (AIT), and group 3 included 72 patients with AIT and elevated levels of anti-thyroglobulin (anti-Tg) and anti-thyroid peroxidase (anti-TPO) antibodies in the serum. We used a pathway-specific polymerase chain reaction (PCR) array (RT2 Profiler™ PCR Array Human Neurotrophins & Receptors, QIAGEN, Germany) to identify and verify neuropeptides and receptors pathway-focused gene expression in 12 individuals that were randomly selected from each group using real-time PCR. Our research identified that patients with postoperative hypothyroidism had a considerably increased expression of NPY1R, NTSR1, and NPY4R. The patients with hypothyroidism caused by autoimmune thyroiditis had considerably lower expression of NTSR1, while the expression of NPY1R increased. The mRNA levels of NPY2R and PNOC increased in the patients with elevated levels of autoantibodies anti-Tg and anti-TPO in the serum, and mRNA levels of NPY1R and NTSR1 decreased in this group of patients. ©2021 JOURNAL of MEDICINE and LIFE.Entities:
Keywords: autoimmune thyroiditis; hypothyroidism; mRNA; neuropeptides
Year: 2021 PMID: 34104248 PMCID: PMC8169137 DOI: 10.25122/jml-2020-0183
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Clinical characteristics of the subjects.
| Control group (n=25) | Patients with postoperative hypothyroidism (Group 1) (n=16) | Patients with hypothyroidism as a result of AIT (Group 2) (n=65) | Patients with AIT and rising serum levels of anti-Tg and anti-TPO autoantibodies (Group 3) (n=72) | |
|---|---|---|---|---|
| 46.08±14.58 | 47.30±12.27 | 46.72±15.49 | 45.02±13.65 | |
| 8.91±0.97 | 3.44±0.31 | 4.13±0.52 | 8.51±0.82 | |
| 2.67±0.52 | 8.61±0.84 | 7.09±0.50 | 2.38±0.62 | |
| 34.04±3.70 | 36.13±2.78 | 380.62±73.42 | 330.36±50.23 | |
| 15.32±1.97 | 15.50±1.90 | 32.97±4.27 | 36.38±7.70 | |
| None | 110.95±5.25 | 88.46±1.55 | None |
Data are expressed as mean ± standard deviation.
Neuropeptides and receptor pathway-focused gene expression analysis.
| Unigene | Refseq | Symbol | Description |
|---|---|---|---|
| NM_000730 | CCKAR | Cholecystokinin A receptor | |
| NM_000756 | CRH | Corticotropin-releasing hormone | |
| NM_005314 | GRPR | Gastrin-releasing peptide receptor | |
| NM_001524 | HCRT | Hypocretin (orexin) neuropeptide precursor | |
| NM_000529 | MC2R | Melanocortin 2 receptor (adrenocorticotropic hormone) | |
| NM_003717 | NPFF | Neuropeptide FF-amide peptide precursor | |
| NM_053036 | NPFFR2 | Neuropeptide FF receptor 2 | |
| NM_000905 | NPY | Neuropeptide Y | |
| NM_000909 | NPY1R | Neuropeptide Y receptor Y1 | |
| NM_000910 | NPY2R | Neuropeptide Y receptor Y2 | |
| NM_002531 | NTSR1 | Neurotensin receptor 1 (high affinity) | |
| NM_006228 | PNOC | Prepronociceptin | |
| NM_005972 | NPY4R | Pancreatic polypeptide receptor 1 | |
| NM_001058 | TACR1 | Tachykinin receptor 1 | |
| NM_003353 | UCN | Urocortin |
Differential expression of mRNA neuropeptides and receptor pathway-focused genes in patients with different thyroid pathologies.
| Gene Symbol | Up-Down Regulation (comparing to the control group) | ||
|---|---|---|---|
| Patients with postoperative hypothyroidism (Group 1) | Patients with hypothyroidism as a result of AIT (Group 2) | Patients with AIT and rising serum anti-Tg and anti-TPO autoantibodies (Group 3) | |
| Fold Regulation | Fold Regulation | Fold Regulation | |
| -1.2 (p=0.13) | -1.01 (p=0.97) | -1.07 (p=0.62) | |
| -1.05 (p=0.2) | -1.05 (p=0.43) | -1.08 (p=0.06) | |
| -1.08 (p=0.63) | 1.06 (p=0.81) | -1.15 (p=0.49) | |
| -1.05 (p=0.2) | -1.05 (p=0.43) | -1.08 (p=0.06) | |
| -1.05 (p=0.2) | -1.05 (p=0.43) | -1.08 (p=0.06) | |
| -1.05 (p=0.2) | -1.05 (p=0.43) | -1.08 (p=0.06) | |
| -1.17 (p=0.86) | 1.05 (p=0.53) | -1.19 (p=0.12) | |
| -1.16 (p=0.27) | -1.06 (p=0.82) | -1.21 (p=0.12) | |
| 3.0 (p=0.05) | 5.5 (p=0.0006) | -3.16 (p=0.003) | |
| -1.05 (p=0.2) | -1.05 (p=0.43) | 4.63 (p=0.06) | |
| 3.73 (p=0.03) | -3.71 (p=0.007) | -3.56 (p=0.005) | |
| 1.18 (p=0.27) | 1.09 (p=0.62) | 4.63 (p=0.004) | |
| 3.21 (p<0.05) | -1.01 (p=0.95) | 1.01 (p=0.97) | |
| -1.06 (p=0.61) | -1.17 (p=0.34) | -1.13 (p=0.61) | |
| 1.02 (p=0.98) | -1.06 (p=0.92) | -1.21 (p=0.43) | |
The p values are calculated based on a Student's t-test of the replicate 2^(- Delta CT) values for each gene in the control group and study groups.
Figure 1.Cell plot neuropeptides and receptor pathway-focused gene expression analysis.